

Nicole Piche-Nicholas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7513869/publications.pdf>

Version: 2024-02-01

12
papers

485
citations

933447

10
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

693
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishing <i>in vitro in vivo</i> correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. <i>MABs</i> , 2018, 10, 244-255.	5.2	76
2	Atypical Antigen Recognition Mode of a Shark Immunoglobulin New Antigen Receptor (IgNAR) Variable Domain Characterized by Humanization and Structural Analysis. <i>Journal of Biological Chemistry</i> , 2013, 288, 17408-17419.	3.4	74
3	Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. <i>MABs</i> , 2012, 4, 673-685.	5.2	70
4	Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. <i>MABs</i> , 2018, 10, 81-94.	5.2	55
5	Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates. <i>AAPS Journal</i> , 2017, 19, 1123-1135.	4.4	51
6	A Monoclonal Antibody Against RAGE Alters Gene Expression and is Protective in Experimental Models of Sepsis and Pneumococcal Pneumonia. <i>Shock</i> , 2011, 35, 492-498.	2.1	50
7	Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics. <i>Current Drug Metabolism</i> , 2013, 14, 764-790.	1.2	44
8	Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21 Antibody Protein Conjugate. <i>Drug Metabolism and Disposition</i> , 2015, 43, 803-811.	3.3	18
9	Embryo-Fetal Transfer of Bevacizumab (Avasatin) in the Rat Over the Course of Gestation and the Impact of Neonatal Fc Receptor (FcRn) Binding. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2012, 95, 363-375.	1.4	13
10	A Physiologically-Based Pharmacokinetic Model for the Prediction of Half-Life Extension and Catch and Release Monoclonal Antibody Pharmacokinetics. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 534-541.	2.5	13
11	Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 622-631.	7.0	11
12	Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. <i>MABs</i> , 2021, 13, 1850395.	5.2	10